ERBB2 and breast carcinoma: Trastuzumab Deruxtecan (T-DXd) is a significant breakthrough as it is the first HER2-targeted ADC to demonstrate substantial clinical effectiveness and safety in breast cancer patients with low HER2 expression [42].